Experts Debate Clinical Sequencing's Short- and Long-Term Impact on Dx, Therapeutics, Patient Health
March 22, 2011
Experts Debate Clinical Sequencing's Short- and Long-Term Impact on Dx, Therapeutics, Patient Health
"Next-gen sequencing is going to turn diagnostics completely upside down and on its head," Richard Resnick, CEO of GenomeQuest, said at a recent panel discussion on next-gen sequencing-based diagnostics.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- AltheaDx Adds Next-Gen Sequencing Services for Biomarker Discovery, Clinical Trial Testing
June 29, 2011 / Clinical Sequencing News - UK Government Funding Development of Sequencing-Based Cancer Tests
June 21, 2011 / Clinical Sequencing News - Transgenomic Launches NGS-Based Mitochondrial Disease Test, Developing Autism Risk Test
June 21, 2011 / Clinical Sequencing News - Foundation Medicine Shows Sequencing-based Cancer Test Can ID Clinically Actionable Mutations
June 8, 2011 / Clinical Sequencing News - Analyst Says Sequencing-Based Dx Could Be 'Ultimate Opportunity' for Illumina
June 8, 2011 / Clinical Sequencing News